Skip to content
Screener
Neonc Technologies Holdings logo

Neonc Technologies Holdings

NTHI

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel drug candidates and delivery methods for intracranial malignancies.

Market cap
$86.13M-57.9%
Revenue$60.0K
Net income-$47.2M-11.2%
EPS (diluted)-$2.13+8.6%
Trailing twelve months · change vs. prior year

Earnings

Next report

Nov 12, 2026 (in 2 months)
EPS estimate-$0.23

Financials

Q2 2026

Income statement

See full
Revenue-
Operating income-$14.1M-146%
Net income-$14.2M-151%
EPS (diluted)-$0.58-93.3%

Balance sheet

See full
Cash & equivalents$2.0M+1,478%
Total debt$648.2K+63.9%
Total equity-$18.5M-56.8%
Total assets$5.2M+75.1%

Cash flow

See full
Operating cash flow-$4.8M+10.3%

Valuation & ratios

Valuation

See full
Market cap$86.13M-57.9%
Enterprise value$84.8M-58.6%
P/S1,435.7×

Returns & leverage

See full
Current ratio0.2×+0.1×

Competitors

Profile

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel drug candidates and delivery methods for intracranial malignancies. The company focuses on overcoming the blood-brain barrier to treat primary and secondary brain cancers using proprietary intranasal and intra-arterial delivery pathways. Its core value proposition lies in enhancing the central nervous system penetration of chemotherapeutic agents while minimizing systemic toxicity.

Competitive position

A clinical-stage innovator focused on niche CNS delivery technologies and bioconjugated hybrid molecules for hard-to-treat brain malignancies.

GeographiesUnited States, Gulf Cooperation Council region
Customer segmentsPatients, Hospitals, Research Centers
Business modelR&D, Licensing, Biopharmaceutical Development
SuppliersContract Research Organizations (CROs), Third-party contract manufacturers, Academic research institutions, Raw material suppliers
CustomersOncology clinics, Specialty hospitals, Pharmaceutical companies for potential licensing
Listed2025
CEOAmir Farrokh Heshmatpour
FilingsSEC EDGAR

FAQ

What is Neonc Technologies Holdings's market cap?
Neonc Technologies Holdings (NTHI) has a market capitalization of $86.1M and trades on NASDAQ.
What is Neonc Technologies Holdings's revenue and profitability?
Neonc Technologies Holdings generated $60.0K in trailing twelve-month revenue with a net loss of $47.2M, representing a net margin of -51613.3%. The latest reported period is Q2 2026.
Who are Neonc Technologies Holdings's competitors?
Neonc Technologies Holdings's key competitors include Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, and others. These companies compete in similar markets and product categories.
Who does Neonc Technologies Holdings partner with?
Neonc Technologies Holdings's notable partners include University of Southern California, Quazar Investment Group, ClinDatrix, Inc., and others.
What subsidiaries does Neonc Technologies Holdings have?
Neonc Technologies Holdings's subsidiaries include NeOnc Technologies, Inc..
Where is Neonc Technologies Holdings headquartered?
Neonc Technologies Holdings is headquartered in United States of America. It has been publicly traded since 2025.